MAPK10
Mitogen-activated protein kinase 10
As of the edition of 20 October 2026, MAPK10 (mitogen-activated protein kinase 10, UniProt P53779) has 4 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P53779
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 65
- Disease areas
- Ear, nose and throat; Nervous system; Eye; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
- Registered trials of its drugs
- 9
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Brimapitide, c-terminal acid | Stopped | Phase 3 | none listed |
| Brimapitide | Went quiet | Phase 3 | none listed |
| Tanzisertib | Stopped | Phase 2 | none listed |
| Bentamapimod | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| Auris Medical | Route A |
| Xigen | Route A |
The other 1 company at MAPK10
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at MAPK10, ranked, with the facts behind eachRequest access. Nothing is shown until you do.